Roche RT-PCR Technology used for TIB MOLBIOL’s H1N1 Test
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
TIB MOLBIOL, the Berlin-based cooperation partner of Roche Applied Science announced the development of a LightMix test for the new variant of the Influenza A H1N1 virus, to be launched initially in Europe and Asia. This test has been optimized for Roche LightCycler® 480 II, 2.0, and 1.2 systems and selectively identifies the new Influenza A H1N1 virus.
“We are proud of our contribution in the battle against a potential pandemic. The new test proved its suitability this week, after identifying the virus in sample materials from Mexico,” said Olfert Landt, TIB Molbiol.
Manfred Baier, Head of Roche Applied Science, adds: “Roche is committed to supporting governments and institutions worldwide in combating this outbreak of influenza, and we are providing scientists, who are working on Influenza A H1N1 virus, with efficient tools for their work.”
The company is in close contact with various research institutions and test centers worldwide providing assistance in the detection and characterization of Influenza A H1N1 virus. Basing on these contacts Roche Applied Science is developing another test with improved characteristics, which will be available soon, the company says.
“We are proud of our contribution in the battle against a potential pandemic. The new test proved its suitability this week, after identifying the virus in sample materials from Mexico,” said Olfert Landt, TIB Molbiol.
Manfred Baier, Head of Roche Applied Science, adds: “Roche is committed to supporting governments and institutions worldwide in combating this outbreak of influenza, and we are providing scientists, who are working on Influenza A H1N1 virus, with efficient tools for their work.”
The company is in close contact with various research institutions and test centers worldwide providing assistance in the detection and characterization of Influenza A H1N1 virus. Basing on these contacts Roche Applied Science is developing another test with improved characteristics, which will be available soon, the company says.